Pfizer has seen Ruxience, its biosimilar version of Genentech’s Rituxan (rituximab), approved by the FDA in the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukaemia, and granulomatosis with polyangiitis and microscopic polyangiitis. While rheumatoid arthritis is also an approved indication of the reference product, the approval of Ruxience did not cover this disease area.
